Onderzoeker
Armand Van Deun
- Trefwoorden:B230-bacteriologie, B680-volksgezondheid, B725-diagnostiek, B726-klinische-biologie
- Disciplines:Bacteriologie
Affiliaties
- Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf1 jan 1999 → 30 nov 2018 - Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf1 jan 1999 → 16 apr 2015
Projecten
1 - 4 of 4
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without Creating MoreVanaf1 okt 2018 → 30 sep 2024
- Trend and significance of INH resistance in DF BdeshVanaf1 jan 2018 → 31 dec 2018
- Trend of fluoroquinolone resistance among the MDR in DF BangladeshVanaf1 jan 2017 → 31 dec 2018
- Validity and feasability of use of a rapid and innovative test for detection of Multi Drug Resistant (MDR) TB cases in Kinshasa, DRCVanaf1 mrt 2009 → 6 jul 2018
Publicaties
1 - 10 van 143
- Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial(2024)
Auteurs: Jihad Snobre, J Gasana, Jean Claude Semuto Ngabonziza, Isabel Cuella Martin, Leen Rigouts, Bart K Jacobs, Emeline de Viron, Natacha Herssens, JB Ntihumby, A Klibazayre, et al.
- Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh(2023)
Auteurs: Pauline Lempens, Armand Van Deun, Kya J M Aung, Mohammad A Hossain, Mahboobeh Behruznia, Tom Decroo, Leen Rigouts, Bouke de Jong, Conor Meehan
- High rate of adverse drug reactions with a novel tuberculosis retreatment regimen combining triple-doses of both isoniazid and rifampicin(2023)
Auteurs: Mahamadou Bassirou Souleymane, Sani Kadri, Alberto Piubello, Achilleas Tsoumanis, Alphazazi Soumana, Hamidou Issa, Abdoulaziz Kabirou Amoussa, Armand Van Deun, Lut Lynen, Bouke de Jong, et al.
Pagina's: 78-81 - GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis(2023)
Auteurs: Leen Rigouts, Jelle Keysers, Rabab Reenaers, Kristina Fissette, Armand Van Deun, Bouke de Jong
- Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: a retrospective cohort study(2023)
Auteurs: Mahamadou Bassirou Souleymane, Tom Decroo, Saïdou Mamadou, Alphazazi Soumana, Ibrahim Mamane Lawan, Assiatou Gagara-Issoufou, Eric Adehossi, Nimer Ortuño-Gutiérrez, Lut Lynen, Leen Rigouts, et al.
Pagina's: 258–264 - Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB(2022)
Auteurs: D. M. Kokebu, S. Ahmed, R. Moodliar, C.Y. Chiang, Gabriela Torrea, Armand Van Deun, Ruth L. Goodall, I. D. Rusen, S. K. Meredith, A J Nunn
Pagina's: 753-759 - Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation(2022)
Auteurs: Mahamadou Bassirou Souleymane, Tom Decroo, Alphazazi Soumana, Ibrahim Maman Lawan, Assiatou Gagara-Issoufou, Souleymane Halidou-Moussa, Nimer Ortuno-Gutierrez, Eric Adehossi, Saidou Mamadou, Armand Van Deun, et al.
- Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings(2022)
Auteurs: Armand Van Deun, Valentin Bola, Rossin Lebeke, Michel Kayomo Kaswa, Mohamed Anwar Hossain, Mourad Gumusboga, Gabriela Torrea, Bouke de Jong, Leen Rigouts, Tom Decroo
- Pretomanid for tuberculosis: a systematic review(2022)
Auteurs: Tinne Gils, Lut Lynen, Bouke de Jong, Armand Van Deun, Tom Decroo
Pagina's: 31-42 - Implications of bedaquiline-resistant tuberculosis(2022)
Auteurs: Tom Decroo, Armand Van Deun
Pagina's: 166-167